Evidence map›Paper›PMID 34120571›Full record

ArticlePrion2021

Human prion disease surveillance in Spain, 1993-2018: an overview.

Jesús De Pedro-Cuesta, Javier Almazán-Isla, Laura Tejedor-Romero, María Ruiz-Tovar, Fuencisla Avellanal, Alberto Rábano, Miguel Calero, Fernando J García López, Spanish CJD Surveillance Group

Abstract read
In one paragraph

Article in Prion, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jesús De Pedro-CuestaDepartment of Neurodegeneration, Ageing and Mental Health, National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.ORCID 0000-0003-2431-9641
Javier Almazán-IslaDepartment of Neurodegeneration, Ageing and Mental Health, National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.ORCID 0000-0001-8723-339X
Laura Tejedor-RomeroDepartment of Neurodegeneration, Ageing and Mental Health, National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.ORCID 0000-0002-7267-3461
María Ruiz-TovarDepartment of Neurodegeneration, Ageing and Mental Health, National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.ORCID 0000-0002-5102-4905
Fuencisla AvellanalDepartment of Neurodegeneration, Ageing and Mental Health, National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.
Alberto RábanoConsortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Miguel CaleroConsortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.ORCID 0000-0001-5366-3324
Fernando J García LópezDepartment of Neurodegeneration, Ageing and Mental Health, National Epidemiology Centre, Carlos III Health Institute, Madrid, Spain.ORCID 0000-0002-4802-2650
Spanish CJD Surveillance Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Spain, human transmissible spongiform encephalopathies (TSEs) have been undergoing continuous surveillance for over 25 years. In 1995, the system was launched as an EU Concerted Action, with EU surveillance network procedures being incorporated from 2002 onwards. The aim of this report was to describe performance and outcomes of this surveillance system across the period 1993-2018. Neurology and public health specialists from every region reported cases to a central hub at the Carlos III Health Institute, Madrid. In all, eight accidentally transmitted cases and five definite variant Creutzfeldt-Jakob disease (vCJD) patients were reported. All vCJD cases were diagnosed between 2005 and 2008. Two of these were family/dietary-related and spatially linked to a third. Yearly incidence of sporadic CJD per million was 1.25 across the period 1998-2018, and displayed a north-south gradient with the highest incidence in La Rioja, Navarre and the Basque Country. Genetic TSEs were observed to be clustered in the Basque Country, with a 4-fold incidence over the national rate. A total of 120 (5.6%) non-TSE sporadic, conformational, rapidly progressing neurodegenerative and vascular brain disorders were reported as suspect CJD. We conclude that TSEs in Spain displayed geographically uneven, stable medium incidences for the sporadic and genetic forms, a temporal and spatial family cluster for vCJD, and decreasing numbers for dura-mater-associated forms. The vCJD surveillance, framed within the EU network, might require continuing to cover all prion disorders. There is need for further strategic surveillance research focusing on case definition of rapid-course, conformational encephalopathies and surgical risk.

Indexed as

Creutzfeldt-Jakob SyndromeEncephalopathy, Bovine SpongiformPrion DiseasesAnimalsBrainCattleHumansSpaincreutzfeldt-jakob diseaseepidemiologyprion proteinsregistriesspainsurveillanceTransmissible spongiform encephalopathies

Identifiers

PMID34120571
PMCPMC8205053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.